Top

Targeted Oncology

Published in:

01-02-2017 | Systematic Review

mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review

Authors: Cara M. Statz, Sara E. Patterson, Susan M. Mockus

Published in: Targeted Oncology | Issue 1/2017

Abstract

Background

The progression of prostate cancer to castration-resistant prostate cancer (CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of rapamycin) pathway, suggesting that therapies targeting this pathway might lead to improved survival and efficacy. Here, we systematically evaluate the results of clinical trials investigating mTOR inhibition in CRPC and utilize preclinical data to predict clinical outcomes.

Methods

Trials included in the study were identified through PubMed and via review of conference abstracts cited by relevant review articles. The eligibility of trials was independent of sample size, clinical setting, or date.

Results

A total of 14 studies were eligible for qualitative analysis. The clinical setting was variable among studies, and all utilized an allosteric mTOR inhibitor as either a monotherapy or in combination. Molecular criteria were evaluated in three trials. Among most studies, the prostate-specific antigen level declined during treatment, but often increased shortly thereafter. Partial responses to treatment were minimal, and no complete responses were reported. Two studies exploring therapy with an mTOR inhibitor in combination with bicalutamide resulted in minimal efficacy. Overall, allosteric mTOR inhibition was deemed to be inadequate for the treatment of CRPC.

Conclusion

Preclinical data suggest that a reciprocal feedback mechanism between PI3K and androgen receptor signaling is a potential mechanism behind the clinical inefficacy of mTOR inhibitors in CRPC, indicating combinatorial targeting of PI3K, mTORC1/2, and the androgen receptor might be more effective. Comprehensive analysis of preclinical data to assess clinical trial targets and efficacy may reduce the number of unproductive trials and identify potentially beneficial combinatorial therapies for resistant disease.

https://static-content.springer.com/image/art%3A10.1007%2Fs11523-016-0453-6/MediaObjects/11523_2016_453_Figa_HTML.gif

Available only for authorised users

American Cancer Society. Cancer facts & figures 2016. Atlanta: American Cancer Society; 2016.

Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109(1):32–9. doi:10.1111/j.1464-410X.2011.10422.x.CrossRefPubMed

Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 2011;10:20. doi:10.4103/1477-3163.83937.CrossRefPubMedPubMedCentral

Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168(1):9–12.CrossRefPubMed

Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl. 2014;16(3):378–86. doi:10.4103/1008-682X.122876.CrossRefPubMedPubMedCentral

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9. doi:10.1001/jama.294.4.433.CrossRefPubMed

Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33–9. doi:10.1038/nm972.CrossRefPubMed

Schweizer MT, Yu EY. Persistent androgen receptor addiction in castration-resistant prostate cancer. J Hematol Oncol. 2015;8(1):128. doi:10.1186/s13045-015-0225-2.CrossRefPubMedPubMedCentral

Anantharaman A, Friedlander TW. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: a review. Urol Oncol. 2016;34(8):356–67. doi:10.1016/j.urolonc.2015.11.003.

10.

Chan SC, Dehm SM. Constitutive activity of the androgen receptor. Adv Pharmacol. 2014;70:327–66. doi:10.1016/B978-0-12-417197-8.00011-0.CrossRefPubMedPubMedCentral

11.

Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54. doi:10.1158/0008-5472.CAN-08-0249.CrossRefPubMedPubMedCentral

12.

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22. doi:10.1016/j.ccr.2010.05.026.CrossRefPubMedPubMedCentral

13.

Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 2013;20(3):R83–99. doi:10.1530/ERC-12-0394.CrossRefPubMed

14.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–28. doi:10.1016/j.cell.2015.05.001.CrossRefPubMedPubMedCentral

15.

Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283–96. doi:10.1038/nrm3330.PubMed

16.

Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem. 2005;280(37):32081–9. doi:10.1074/jbc.M502876200.CrossRefPubMed

17.

Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003;4(3):209–21.CrossRefPubMed

18.

Nardella C, Carracedo A, Alimonti A, Hobbs RM, Clohessy JG, Chen Z, et al. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal. 2009;2(55):ra2. doi:10.1126/scisignal.2000189.CrossRefPubMedPubMedCentral

19.

Tai S, Sun Y, Liu N, Ding B, Hsia E, Bhuta S, et al. Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther. 2012;11(6):1320–31. doi:10.1158/1535-7163.MCT-11-0954.CrossRefPubMedPubMedCentral

20.

Fagone P, Donia M, Mangano K, Quattrocchi C, Mammana S, Coco M, et al. Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. Basic Clin Pharmacol Toxicol. 2013;112(1):63–9. doi:10.1111/j.1742-7843.2012.00923.x.CrossRefPubMed

21.

Li W, Wang Z, Wang L, He X, Wang G, Liu H, et al. Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. Int J Clin Exp Med. 2015;8(4):6563–7.PubMedPubMedCentral

22.

Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575–86. doi:10.1016/j.ccr.2011.04.008.CrossRefPubMedPubMedCentral

23.

Lee SH, Johnson D, Luong R, Sun Z. Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells. J Biol Chem. 2015;290(5):2759–68. doi:10.1074/jbc.M114.607846.CrossRefPubMed

24.

Patterson SE, Liu R, Statz CM, Durkin D, Lakshminarayana A, Mockus SM. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. Hum Genom. 2016;10(1):4. doi:10.1186/s40246-016-0061-7.CrossRef

25.

Meng S, Cao J, He Q, Xiong L, Chang E, Radovick S, et al. Metformin activates AMP-activated protein kinase by promoting formation of the alphabetagamma heterotrimeric complex. J Biol Chem. 2015;290(6):3793–802. doi:10.1074/jbc.M114.604421.CrossRefPubMed

26.

Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol. 2013;63(4):709–16. doi:10.1016/j.eururo.2012.12.004.CrossRefPubMed

27.

Clyne M. Should we give metformin to all men with CRPC? Nat Rev Urol. 2014;11(2):63. doi:10.1038/nrurol.2014.7.CrossRefPubMed

28.

Raval AD, Thakker D, Vyas A, Salkini M, Madhavan S, Sambamoorthi U. Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2015;18(2):110–21. doi:10.1038/pcan.2014.52.CrossRefPubMedPubMedCentral

29.

Amato RJ, Jac J, Mohammad T, Saxena S. Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2008;6(2):97–102. doi:10.3816/CGC.2008.n.015.CrossRefPubMed

30.

Bhat M, Charlton M. Preserving flow in liver transplant recipients: mTOR inhibitors everolimus and sirolimus are not peas from a pod. Am J Transplant. 2013;13(7):1633–5. doi:10.1111/ajt.12290.CrossRefPubMed

31.

Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5. doi:10.1200/JCO.2007.12.4008.CrossRefPubMed

32.

Armstrong AJ, Shen T, Halabi S, Kemeny G, Bitting RL, Kartcheske P, et al. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer. 2013;11(4):397–406. doi:10.1016/j.clgc.2013.05.007.CrossRefPubMed

33.

Kruczek K, Ratterman M, Tolzien K, Sulo S, Lestingi TM, Nabhan C. A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naive castration-resistant prostate cancer. Br J Cancer. 2013;109(7):1711–6. doi:10.1038/bjc.2013.530.CrossRefPubMedPubMedCentral

34.

Emmenegger U, Booth CM, Berry S, Sridhar SS, Winquist E, Bandali N, et al. Temsirolimus maintenance therapy after docetaxel induction in castration-resistant prostate cancer. Oncologist. 2015;20(12):1351–2. doi:10.1634/theoncologist.2015-0220.CrossRefPubMedPubMedCentral

35.

Aggarwal R, Ryan CJ. Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist. 2011;16(3):264–75. doi:10.1634/theoncologist.2010-0216.CrossRefPubMedPubMedCentral

36.

Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011;17(18):6052–60. doi:10.1158/1078-0432.CCR-10-2979.CrossRefPubMedPubMedCentral

37.

Rathkopf DE, Danila DC, Morris MJ, Slovin SF, Borwick LS, Momen L, et al. Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): results of a phase I pilot study. J Clin Oncol. 2011;29(suppl; abstr e15081).

38.

Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bartschi D, Droge C, et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol. 2013;64(1):150–8. doi:10.1016/j.eururo.2013.03.040.CrossRefPubMed

39.

Gross ME, Soscia J, Sakowsky S, Castellanos O, Agus DB. Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC). J Clin Oncol. 2009;27:15s(suppl; abstr 5154).

40.

Gross TBD ME, Quinn DI, Massopust K, Diaz PM, Castellanos OO, Agus DB. Safety and efficacy of everolimus (E), bevacizumab (B), and docetaxel (D) for castration resistant prostate cancer (CRPC). J Clin Oncol. 2015;33(suppl; abstr 5066).

41.

Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, et al. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012;110(11):1729–35. doi:10.1111/j.1464-410X.2012.11456.x.CrossRefPubMed

42.

Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29(27):3695–704. doi:10.1200/JCO.2011.35.8648.CrossRefPubMedPubMedCentral

43.

Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, et al. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(2):113–23. doi:10.1016/j.clgc.2014.08.007.CrossRefPubMed

44.

Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res. 2003;63(23):8451–60.PubMed

45.

Vaishampayan U, Shevrin D, Stein M, Heilbrun L, Land S, Stark K, et al. Phase II trial of carboplatin, everolimus, and prednisone in metastatic castration-resistant prostate cancer pretreated with docetaxel chemotherapy: a prostate cancer clinical trial consortium study. Urology. 2015;86(6):1206–11. doi:10.1016/j.urology.2015.08.008.CrossRefPubMed

46.

Rathkopf DE, Larson SM, Anand A, Morris MJ, Slovin SF, Shaffer DR, et al. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: phase 1/2 results and signaling pathway implications. Cancer. 2015;121(21):3853–61. doi:10.1002/cncr.29578.CrossRefPubMedPubMedCentral

47.

Perotti A, Locatelli A, Sessa C, Hess D, Vigano L, Capri G, et al. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol. 2010;28(30):4554–61. doi:10.1200/JCO.2009.27.5867.CrossRefPubMed

48.

Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross ME. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer. 2012;10(4):232–8. doi:10.1016/j.clgc.2012.05.001.CrossRefPubMedPubMedCentral

49.

Meulenbeld HJ, de Bono JS, Tagawa ST, Whang YE, Li X, Heath KH, et al. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). Cancer Chemother Pharmacol. 2013;72(4):909–16. doi:10.1007/s00280-013-2250-6.CrossRefPubMed

50.

Cockshott ID. Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855–78.CrossRefPubMed

51.

Klumpen HJ, Beijnen JH, Gurney H, Schellens JH. Inhibitors of mTOR. Oncologist. 2010;15(12):1262–9. doi:10.1634/theoncologist.2010-0196.CrossRefPubMedPubMedCentral

52.

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12. doi:10.1056/NEJMoa040720.CrossRefPubMed

53.

Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20. doi:10.1056/NEJMoa041318.CrossRefPubMed

54.

Chandrasekar T, Yang JC, Gao AC, Evans CP. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015;13:206. doi:10.1186/s12916-015-0457-6.CrossRefPubMedPubMedCentral

55.

Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003;1(3):E59. doi:10.1371/journal.pbio.0000059.CrossRefPubMedPubMedCentral

56.

Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, et al. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther. 2013;12(11):2342–55. doi:10.1158/1535-7163.MCT-13-0032.CrossRefPubMed

57.

Chang L, Graham PH, Ni J, Hao J, Bucci J, Cozzi PJ, et al. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Crit Rev Oncol Hematol. 2015;96(3):507–17. doi:10.1016/j.critrevonc.2015.07.005.CrossRefPubMed

58.

Garcia-Echeverria C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett. 2010;20(15):4308–12. doi:10.1016/j.bmcl.2010.05.099.CrossRefPubMed

59.

Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12–rapamycin complex interacting with the binding domain of human FRAP. Science. 1996;273(5272):239–42.CrossRefPubMed

60.

Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, et al. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer. 2014;134(10):2322–9. doi:10.1002/ijc.28579.CrossRefPubMed

61.

Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012;485(7396):55–61. doi:10.1038/nature10912.CrossRefPubMedPubMedCentral

62.

Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11(2):317–28. doi:10.1158/1535-7163.MCT-11-0474.CrossRefPubMed

63.

Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell. 2009;16(6):458–62. doi:10.1016/j.ccr.2009.11.006.CrossRefPubMed

64.

Qi W, Morales C, Cooke LS, Johnson B, Somer B, Mahadevan D. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer. Oncotarget. 2015;6(39):41976–87. doi:10.18632/oncotarget.5659.PubMedPubMedCentral

Title: mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
Authors: Cara M. Statz
Sara E. Patterson
Susan M. Mockus
Publication date: 01-02-2017
Publisher: Springer International Publishing
Published in: Targeted Oncology / Issue 1/2017
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-016-0453-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

Erratum to: Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model

Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action

Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry

The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences

Keynote webinar | Spotlight on antibody–drug conjugates in cancer